e-Therapeutics plc announces that regulatory agencies in the United Kingdom and the United States have approved plans for Phase 1 trials of the company’s anticancer drug ETS2101 and that enrollment of patients into trials in these two countries will begin shortly.
A Phase 1 trial in the U.K. will recruit patients with a variety of solid tumors, while a US investigator-led trial will enrol patients with primary or secondary brain cancers. Further details of each trial will be provided when its first patient is treated.
Professor Malcolm Young, CEO of e-Therapeutics, said: “We remain on track to report the first data from cancer trials with ETS2101 and to advance three further drugs into the clinic by the end of this year.”
Date: March 29, 2012
Source: e-Therapeutics plc
Filed Under: Drug Discovery
